deleted from the paragraph is indicated by brackets and matter that has been added to the paragraph is indicated by underlining.

In the Claims:

Please amend the claims as follows:

Please cancel Claims 1 through 20, without prejudice.

Please add the following new Claims 21-40.

21. (New) An isolated nucleic acid molecule comprising a nucleotide sequence encoding an endostatin protein or an angiogenic inhibitory peptide fragment thereof.

22. (New) The isolated nucleic acid molecule of Claim 21, wherein said nucleotide sequence comprises SEQ ID NO. 4, or a substantially homologous sequence to SEQ ID NO. 4.

23. (New) The isolated nucleic acid molecule of Claim 21, wherein said nucleotide sequence comprises SEQ ID NO. 6, or a substantially homologous sequence to SEQ ID NO. 6.

24. (New) The isolated nucleic acid molecule of Claim 21 encoding an endostatin protein or peptide fragment comprising SEQ ID NO. 1, 2, 3, or 5, or a sequence substantially homologous to SEQ ID NO. 1, 2, 3, or 5.

25. (New) An isolated nucleic acid molecule encoding a polypeptide having an N-terminal fragment comprising the amino acid sequence of SEQ ID NO. 1, or an N-terminal fragment substantially

homologous to SEQ ID NO. 1, wherein said polypeptide is an inhibitor of endothelial cell proliferation.

26. (New) The isolated nucleic acid molecule of Claim 25, wherein said polypeptide is endostatin or a peptide fragment thereof.

27. (New) The isolated nucleic acid molecule of Claim 26, wherein said endostatin or peptide fragment is a fragment of a C-terminal non-collagenous region of a non-fibrillar collagen molecule.

28. (New) The isolated nucleic acid molecule of Claim 26, wherein said endostatin or peptide fragment binds to a heparin affinity column and does not bind to a lysine affinity column.

29. (New) The isolated nucleic acid molecule of Claim 27, wherein said collagen molecule comprises collagen type XVIII or XV.

30. (New) The isolated nucleic acid molecule of Claim 25, encoding a polypeptide comprising at least an 18 N-terminal amino acid sequence of SEQ ID NO. 1, or a polypeptide having an N-terminal fragment substantially homologous to the 18 N-terminal amino acid sequence of SEQ ID NO. 1.

31. (New) A vector comprising the nucleotide acid molecule of Claim 25 operatively linked to a regulatory control element capable of expressing the nucleotide sequence of the nucleic acid molecule in an eukaryotic or a prokaryotic cell, *in vivo* or *in vitro*.

32. (New) A host cell containing the vector of Claim 31.

33. (New) A pharmaceutical composition comprising:

a) a polypeptide comprising the amino acid sequence of SEQ ID NO. 1, 2, 3, or 5, or a sequence that is substantially homologous to SEQ ID NO. 1, 2, 3, or 5;

b) a naturally or synthetically produced derivative, analog, or variant of a polypeptide having the amino acid sequence of SEQ ID NO.1, 2, 3, or 5, or a sequence that is substantially homologous to SEQ ID NO.1, 2, 3, or 5;

c) a polypeptide which is encoded by a nucleotide sequence comprising SEQ ID NO. 4 or 6, or a sequence that is substantially homologous to SEQ ID NO. 4 or 6;

d) a nucleic acid molecule comprising the nucleotide sequence of SEQ ID NO. 4 or 6, or a nucleotide sequence that is substantially homologous to SEQ ID NO. 4 or 6;

e) a vector comprising a nucleic acid molecule of SEQ ID NO. 4 or 6, or a nucleotide sequence that is substantially homologous to SEQ ID NO. 4, or 6;

f) an antibody to a polypeptide comprising the amino acid sequence of SEQ ID NO.1, 2, 3, or 5 or an amino acid sequence that is substantially homologous to SEQ ID NO.1, 2, 3, or 5;

g) a host cell genetically transformed with a nucleic acid molecule encoding a polypeptide comprising the amino acid sequence of SEQ ID NO. 1, 2, 3, or 5 or an amino acid sequence that is substantially homologous to said SEQ ID NO. 1, 2, 3, or 5; and

a pharmaceutically acceptable carrier or diluent.

34. (New) The pharmaceutical composition of Claim 33 formulated as a sustained release for a period of at least 8 hours.

35. (New) The composition of Claim 33 administered to an individual for the treatment of an angiogenesis-related disease.

36. (New) The composition of Claim 33, wherein the angiogenesis-related disease is an angiogenesis-dependent cancer.

37. (New) The composition of claim 33, wherein said nucleic acid molecule encodes an endostatin protein or an angiogenic inhibitory peptide fragment thereof.

38. (New) The composition of Claim 33, wherein the endostatin protein or peptide fragment is a fragment of a C-terminal non-collagenous region of a non-fibrillar collagen protein that binds to a heparin affinity column and does not bind to a lysine affinity column.

39. (New) The composition of Claim 38, wherein said collagen protein or peptide fragment comprises collagen types XVIII, or XV.

40. (New) The composition of Claim 35, wherein the endostatin protein or peptide fragment is derived from a human.